PharmacovigilanceOfficial

Commission grants marketing authorisation for ensartinib product Gevalka to SFL Pharmaceuticals Deutschland

🇪🇺 European Commission (Union Register) · Mon 16 Nov 2026

Commission Decision (2026) 8320 of 16 November 2026 authorises Gevalka (ensartinib) in the EU, with SFL Pharmaceuticals Deutschland GmbH named as marketing authorisation holder.

The European Commission has granted a new marketing authorisation for Gevalka, whose active substance is ensartinib. The authorisation was issued through Commission Decision (2026) 8320 of 16 November 2026, and the holder is SFL Pharmaceuticals Deutschland GmbH.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Official source: European Commission (Union Register) ↗

Article written by VigiEye from the official source (European Commission (Union Register)). AI-assisted; check the source before acting.